KEYNOTE-695

Interim Data Presented at SITC 2020

CORVax12

IND for COVID-19 Vaccine Candidate Accepted by FDA

TAVO™

Investigational Intratumoral Cancer Immunotherapy

OncoSec’s VLA: Visceral Lesion Applicator

KEYNOTE-890

Clinical trial currently recruiting patients with TNBC

News & Events

OncoSec Corporate Presentation

Listen to Presentation

Watch the Event

Join the Webinar

Featured Articles

Annals of Oncology

Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients.

March 16, 2020

Clinical Cancer Research

Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma.

February 1, 2020

Nature Gene Therapy

Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy.

September 30, 2019

Designed to Arm the Immune System to Fight Cancer

We are investigating the potential for our lead product candidate, TAVO, through the intratumoral administration of IL-12, to stimulate systemic immune response and to become an innovative and potentially transformative therapy option for the treatment of cancer.

Clinical Pipeline

Our core technology platform continues to advance through clinical trials for various cancers

Learn More

Technology

Our plasmid DNA delivery platform is designed to boost the body’s immune system to target and attack cancer

Learn More

Partnerships

We have a track record of establishing, operating and evolving high-performance partnerships globally

Learn More

It's all about you

Visit our Patient Portal

New Approaches, New Hope

Learn More About Oncosec

“TAVO” IL-12

Fighting tumors directly.